A Better Prognosis for Big Pharma

Concerns remain, but new products, improving R&D, and the continued validity of major patents may have eased the industry's ratings slide

From Standard & Poor's RatingsDirect

To continue reading this article you must be a Bloomberg Professional Service Subscriber.